Evidence review
How Many Units Is a Microdose in an Ozempic or Wegovy Pen?
People ask how many clicks or units make a GLP-1 microdose. We explain the math honestly — and why Novo Nordisk designs against click-counting.
Written Lena Ortiz
One of the most common questions in microdosing forums is mechanical, not medical: how many clicks, or how many units, is a "microdose" in an Ozempic or Wegovy pen? People reach for this question because a branded pen is expensive and they want to stretch it, or because they want a dose below the lowest step on the official ladder. This page answers the math honestly — but the honest answer comes with a warning that the marketing around microdosing tends to bury: the way these pens are built, click-counting to hit a custom sub-dose is exactly what the manufacturer designed against, and it is an easy way to dose yourself wrong.
So we'll do two things. We'll explain how the pens actually deliver dose — and why "18 clicks ≈ 0.25 mg" is a rough folk-conversion, not a manufacturer instruction. And we'll be clear that if your real goal is a controlled low dose, a compounded vial measured in true units is a more honest tool than improvising on a fixed-dose pen — with its own caveats.
First, the honest framing: there is no approved "microdose"
Before any math: no GLP-1 manufacturer makes a microdose, and no trial has tested intentional microdosing. The Wegovy and Ozempic labels define a fixed ladder of approved doses, and the lowest rung — 0.25 mg once weekly for semaglutide — is a starter dose meant to build tolerance on the way up, not a maintenance dose proven to do much on its own 1. A "microdose" sits below even that starter step, in territory no label and no randomized trial covers 2. Everything below is about the mechanics of the device, not an endorsement that a sub-starter dose works.
Where a microdose sits
Microdose
Below 0.25 mg — no label, no trial
0.25 mg / week
Starter step, builds tolerance
2.4 mg / week
Full dose — where evidence comes from
How the pens actually deliver a dose
This is where Ozempic and Wegovy differ, and the difference matters for anyone counting clicks.
The Ozempic pen is a multi-dose, dial-a-dose device. A single Ozempic pen is designed to deliver several fixed doses from one cartridge — you dial the dose, and the pen meters it out. The pen audibly clicks as it dials, which is the origin of the "count the clicks" folklore. The Ozempic label specifies the discrete doses the pen is built to give (for example 0.25 mg and 0.5 mg from the lower-strength pen) and instructs the user to dial to the marked dose, not to an arbitrary point between marks 3.
The Wegovy single-dose pen is the opposite. Most Wegovy pens are single-use, fixed-dose injectors: one pen, one pre-set dose, no dial. There is nothing to "count" — you press and the full pre-set dose goes in. That design makes Wegovy essentially impossible to microdose without physically defeating the device, which is not a thing the label contemplates or supports 1.
So the "how many units is a microdose" question is really an Ozempic-pen question, dressed up.
The folk math — and why it's only folk math
Here is the conversion people circulate, stated plainly so we can then knock it down. Ozempic's lower-strength pen holds 2 mg of semaglutide in 1.5 mL and is built to give 0.25 mg or 0.5 mg doses 3. People who count clicks report that a full 0.25 mg dose corresponds to roughly 18–19 clicks on that pen, so they reason that "half a click is half the drug" and dial a fraction to chase a microdose.
The arithmetic is internally consistent, but it rests on assumptions the manufacturer never validated:
- The pen is not graduated for sub-doses. Its dose window shows the approved doses, not units. Stopping between marks means you are estimating, not measuring 3.
- Click-to-dose linearity is assumed, not guaranteed. A consistent dose depends on a full, uninterrupted press to the stop; partial actuations can under-deliver unpredictably, and air or priming losses are not evenly distributed across "clicks."
- It voids the one thing a fixed-dose pen is good at — accuracy. The entire reason a dial-a-dose pen exists is to remove guesswork; counting clicks to a custom number puts the guesswork back.
This is why the clinical literature that addresses microdosing treats pen manipulation as a safety hazard — flagging dosing errors and device misuse rather than offering a clicks-to-milligrams chart 2. We are giving you the folk math so you understand what people mean, not because it's a reliable way to dose a potent drug.
Pen by pen
| Ozempic pen | Wegovy pen | Compounded vial | |
|---|---|---|---|
| Type | Multi-dose dial-a-dose | Single-dose fixed injector | Vial + insulin syringe |
| Can you 'count units'? | Clicks only — not graduated for sub-doses | No dial, nothing to count | Yes — true volume in units |
| Microdose feasible? | Only by defeating the design | Effectively no | Yes, but measurement ≠ proven benefit |
| Main caveat | Click-counting = dosing error risk | Fixed dose by design | Grey-market; prep/contamination risk |
Why a compounded vial is the more honest low-dose tool
If your actual goal is a deliberately low, measured dose, the device built for that is a vial and a syringe — not a fixed-dose pen you're fighting against. With a compounded vial of known concentration (say, milligrams per milliliter), you draw a true volume in insulin-syringe units, and the dose is something you can calculate and repeat rather than estimate by ear. That's why most people who microdose in practice use compounded product, not a manipulated brand pen 2.
But "more honest tool" is not "safe and proven." Compounded GLP-1s are not FDA-approved finished drugs, and a pharmacovigilance analysis of compounded GLP-1 agonists found markedly elevated reporting odds for preparation errors (reporting odds ratio roughly 48.9), contamination (about 19.0), and compounding problems (about 8.5), alongside more reports of abdominal pain, gallbladder inflammation, and hospitalization 4. So the trade is real: a vial lets you measure a low dose accurately, but it shifts you onto a grey-market product with its own documented risks. We dig into that in is compounded / microdosed GLP-1 safe? and walk through legitimate access routes in how to get microdosing tirzepatide.
What even a correctly measured low dose can — and can't — promise
Suppose you nail the measurement. The deeper problem remains: a sub-therapeutic dose is, by definition, below where the benefits were demonstrated. Semaglutide works by mimicking the gut hormone GLP-1 — slowing gastric emptying, suppressing glucagon, and acting on appetite centers in the brain — and those effects depend on enough drug being present to occupy enough receptors 5. Dose-finding data show weight loss shrinking steadily as the dose falls: in a phase 2 dose-ranging trial, semaglutide produced about 6% weight loss at 0.05 mg versus roughly 14% at the top dose tested 6, and the headline STEP 1 result (about 14.9% mean loss) came from the full 2.4 mg dose 7. A microdose sits below even the lowest dose in that trial. Getting the units right doesn't change the dose-response reality, which we cover in GLP-1 dose-response: why lower doses do less.
The bottom line on clicks and units
The clicks-to-milligrams conversion people pass around (roughly 18 clicks per 0.25 mg on the low-strength Ozempic pen) exists, and we've explained it — but it's folklore layered on top of a device that was engineered specifically to prevent improvised dosing. Novo Nordisk discourages click-counting because a fixed-dose pen's whole value is accuracy, and counting clicks to a custom sub-dose throws that away and invites dosing error 23. Wegovy's single-dose pens can't be microdosed at all without defeating the device. If you genuinely want a controlled low dose, a compounded vial measured in real units is the more honest instrument — but it carries its own compounding and contamination risks 4, and no amount of careful measurement makes a sub-therapeutic dose match the benefits proven at the full dose 67. Talk to a qualified clinician before improvising with any GLP-1 device.
For the bigger picture, start with our pillar, microdosing GLP-1: what the evidence actually shows, and our deep dive on microdosing semaglutide. For a visual map of where doses sit, see our GLP-1 microdosing dose chart, and to compare providers, our GLP-1 microdose rankings hub.
Frequently asked
How many units is a microdose in an Ozempic pen?
There is no official answer, because the Ozempic pen is not graduated in units — it's a dial-a-dose device built to deliver fixed approved doses (like 0.25 mg and 0.5 mg). People circulate a folk conversion of roughly 18 clicks per 0.25 mg, but counting clicks to a custom sub-dose is unvalidated, defeats the pen's built-in accuracy, and is treated as a dosing-error hazard in the clinical literature. Novo Nordisk discourages it.
Can you microdose a Wegovy pen?
Effectively no. Most Wegovy pens are single-use, fixed-dose injectors with no dial — one pen delivers one pre-set dose. There is nothing to count or adjust, so a Wegovy pen can't be microdosed without physically defeating the device, which the label does not support.
Is a compounded vial better for microdosing than a brand pen?
It's a more honest measuring tool, because a vial of known concentration lets you draw a true low dose in insulin-syringe units rather than guessing between pen clicks. But it's not safer overall: compounded GLP-1s are not FDA-approved, and pharmacovigilance data show elevated reports of preparation errors, contamination, and compounding problems. Measuring accurately doesn't make a sub-therapeutic dose match full-dose benefits.
Why does the manufacturer discourage click-counting?
Because a fixed-dose pen's entire value is accuracy. It's engineered to deliver a precise, repeatable dose with a full press to the stop. Counting clicks to land on a custom number between the marked doses reintroduces the exact guesswork the device was designed to remove, and partial actuations can under-deliver unpredictably.
References
- Novo Nordisk (manufacturer label) (2024). WEGOVY (semaglutide) injection — FDA prescribing information (Dosage and Administration; single-dose pen; escalation schedule to 2.4 mg). DailyMed (NIH/NLM), FDA label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Trainer N, et al. (2026). The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. Journal of the American Association of Nurse Practitioners. https://pubmed.ncbi.nlm.nih.gov/42201545/
- Novo Nordisk (manufacturer label) (2024). OZEMPIC (semaglutide) injection — FDA prescribing information (Dosage and Administration; multi-dose pen; 0.25 mg and 0.5 mg dose settings). DailyMed (NIH/NLM), FDA label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- McCall KL, et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety. https://pubmed.ncbi.nlm.nih.gov/40285721/
- Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/29617641/
- O'Neil PM, et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. https://pubmed.ncbi.nlm.nih.gov/30122305/
- Wilding JPH, et al. (STEP 1) (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Microdosing GLP-1: What the Evidence Actually Shows
An honest, citation-backed look at GLP-1 microdosing — an unstudied, off-label practice. What the trials prove, and why less dose means less effect.
Does Microdosing GLP-1 Actually Work?
Does microdosing GLP-1 work? Honestly: no trial has tested it. Here's what dose-response data and standard-dose trials imply, and why anecdotes aren't evidence.
GLP-1 Dose-Response: Why Lower Doses Do Less
The dose-response data are clear: lower GLP-1 doses do less. The semaglutide dose-finding figures, the tirzepatide tiers, and why exposure matters.
Is Compounded / Microdosed GLP-1 Safe?
Compounded and microdosed GLP-1 carry documented safety signals — dosing errors, contamination, GI risk. What the pharmacovigilance and clinical data show.
Microdosing Tirzepatide: What It Is & What the Evidence Actually Says
Microdosing tirzepatide means taking a fraction of a standard dose off-label. There is no trial of it, and dose-response data say lower doses do less.
Microdosing Tirzepatide Dose Chart: How People Titrate (and the Risks)
The microdose schemes people share online vs the real FDA dose ladder — plus the dosing-error and compounding risks. Not medical advice.
Microdosing Semaglutide: Does a Sub-Therapeutic Dose Do Anything?
Microdosing semaglutide means taking a sub-therapeutic dose. Honestly, no trial has tested it — and the dose-finding data say lower doses do less.
Low-Dose vs Full-Dose GLP-1: What Actually Changes
Lower GLP-1 doses mean fewer side effects but less weight loss and no proven cardiometabolic benefit. An honest, evidence-based look at the real tradeoff.
GLP-1 Microdosing Chart: Semaglutide & Tirzepatide
The microdose schemes people share for semaglutide and tirzepatide, side by side with the real FDA dose ladders — plus the risks. Not medical advice.
What Is Microdosing Tirzepatide? A Plain Explainer
A plain explainer of microdosing tirzepatide: what it means, how it differs from standard dosing, and why it's an off-label, unproven practice.
Is Microdosing GLP-1 Safe? The Off-Label Trend's Real Risks
Microdosing GLP-1 is off-label, Rx-only, and untested in trials. The real risks: dosing errors, compounded sourcing, GI effects, and no monitoring.
GLP-1 Microdosing for "Metabolic Optimization" & Longevity: Evidence Check
Does a GLP-1 microdose optimize metabolism or extend lifespan? No longevity RCT exists at any dose — and none at microdoses. The honest evidence check.
Who's Microdosing GLP-1, and Why
Who microdoses GLP-1 and the motivations behind it — weight maintenance, side-effect avoidance, cost, longevity. An honest look at an unproven, off-label trend.
How to Get Microdosing Tirzepatide: Routes, Costs & Honest Caveats
There is no FDA-approved microdose of tirzepatide. Here are the real routes people use to get it, what they cost, the legal status, and the risks.
Microdosing GLP-1 for Perimenopause & Menopause: Honest Evidence
Women report appetite and energy help from low-dose GLP-1 in menopause. But no microdose trial exists, it's off-label, and the muscle-loss risk is real.
Does Microdosing GLP-1 Help PCOS? An Honest Evidence Check
Full-dose GLP-1 drugs improve weight and metabolism in PCOS trials. But no microdose study exists, it's off-label, and lifestyle plus metformin stay front-line.
Microdosing GLP-1 for Insulin Resistance & Prediabetes: Evidence
The mechanism is plausible, but no microdose trial exists for insulin resistance or prediabetes — and metformin is a cheap, evidence-backed comparator.
Microdosing GLP-1 for Inflammation & Longevity: Evidence Check
GLP-1 lowers inflammation — but only at full doses in trials. The low-dose anti-inflammatory and longevity claim is extrapolation, not proof. Honest review.
Using a Microdose to Maintain Weight Loss: What the Evidence Says
Can a low maintenance dose hold your weight loss? Trials show staying on a GLP-1 beats stopping — but a true microdose is untested. The honest evidence.
How to Taper Off GLP-1 Without Regaining: An Honest Guide
Tapering off a GLP-1 doesn't prevent regain on its own — the trials are blunt. Here's a sensible step-down and what actually protects your weight loss.
Microdosing GLP-1 and Muscle Loss: Does a Smaller Dose Protect Lean Mass?
Any GLP-1 weight loss costs some muscle. An honest look at whether microdosing reduces lean-mass loss — and why protein and resistance training matter more.
Microdosing Retatrutide: What the Triple-Agonist Data Actually Show
Retatrutide is investigational — not FDA-approved. Even its lowest trial dose, 1 mg, drove real weight loss. Why microdosing it is a grey-market bet.
Can You Microdose Rybelsus (Oral Semaglutide)? The Honest Answer
Rybelsus 3 mg is a tolerability starter, not a therapeutic dose — and its tablet absorption is so finicky that splitting it is a bad idea. Here's the evidence.
How Much Weight Can You Lose Microdosing GLP-1?
Low-dose GLP-1 reports cluster around ~12% — but there's no RCT, and full-dose trials show 15–21%. An honest look at what a microdose really delivers.